tiprankstipranks
Hemab Therapeutics Holdings, Inc. (COAG)
NASDAQ:COAG
US Market

Hemab Therapeutics Holdings, Inc. (COAG) Stock Forecast & Price Target

11 Followers
See the Price Targets and Ratings of:

COAG Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Hemab
Therapeutics Holdings, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

COAG Stock 12 Month Forecast

Average Price Target

$41.75
Based on 4 Wall Street analysts offering 12 month price targets for Hemab Therapeutics Holdings, Inc. in the last 3 months. The average price target is $41.75 with a high forecast of $50.00 and a low forecast of $36.00. The average price target represents a change from the last price of .
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","51":"$51","32.25":"$32.3","38.5":"$38.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,32.25,38.5,44.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.13,28.889230769230767,30.64846153846154,32.40769230769231,34.16692307692308,35.926153846153845,37.68538461538461,39.44461538461539,41.20384615384616,42.963076923076926,44.722307692307695,46.48153846153846,48.24076923076923,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.13,28.254615384615384,29.37923076923077,30.503846153846155,31.628461538461536,32.753076923076925,33.87769230769231,35.002307692307696,36.12692307692308,37.25153846153846,38.37615384615385,39.50076923076923,40.62538461538462,{"y":41.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.13,27.81230769230769,28.494615384615383,29.176923076923075,29.85923076923077,30.54153846153846,31.223846153846154,31.906153846153845,32.58846153846154,33.27076923076923,33.95307692307692,34.635384615384616,35.31769230769231,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.13,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$41.75Lowest Price Target$36.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$39
Buy
Reiterated
06/08/26
Jefferies Reiterates Buy on Hemab Therapeutics, Maintains $39 Price Target on VWD Opportunity and Differentiated Mechanism
Evercore ISI Analyst forecast on COAG
Evercore ISI
Evercore ISI
$50
Buy
Initiated
05/26/26
Hemab Therapeutics initiated with an Outperform at Evercore ISIHemab Therapeutics initiated with an Outperform at Evercore ISI
Wedbush
$42
Buy
Initiated
05/26/26
Hemab Therapeutics initiated with an Outperform at WedbushHemab Therapeutics initiated with an Outperform at Wedbush
Goldman Sachs Analyst forecast on COAG
Goldman Sachs
Goldman Sachs
$36
Buy
Initiated
05/26/26
Analyst Initiates Buy on Hemab, Citing Differentiated Bleeding-Disorder Pipeline and Multi‑Billion‑Dollar Peak Sales Potential
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$39
Buy
Reiterated
06/08/26
Jefferies Reiterates Buy on Hemab Therapeutics, Maintains $39 Price Target on VWD Opportunity and Differentiated Mechanism
Evercore ISI Analyst forecast on COAG
Evercore ISI
Evercore ISI
$50
Buy
Initiated
05/26/26
Hemab Therapeutics initiated with an Outperform at Evercore ISIHemab Therapeutics initiated with an Outperform at Evercore ISI
Wedbush
$42
Buy
Initiated
05/26/26
Hemab Therapeutics initiated with an Outperform at WedbushHemab Therapeutics initiated with an Outperform at Wedbush
Goldman Sachs Analyst forecast on COAG
Goldman Sachs
Goldman Sachs
$36
Buy
Initiated
05/26/26
Analyst Initiates Buy on Hemab, Citing Differentiated Bleeding-Disorder Pipeline and Multi‑Billion‑Dollar Peak Sales Potential
Stocks with the Highest Top Analyst Consensus in the General Sector
AVEXAEVEX Corp. Class A
GENBGenerate Biomedicines, Inc.
KLRAKailera Therapeutics, Inc.
HMHHMH Holding Inc. Class A
SGPSpyGlass Pharma
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hemab Therapeutics Holdings, Inc.

3 Months
Richard Law CFAGoldman Sachs
Success Rate
0/1 ratings generated profit
0%
Average Return
-9.10%
Copying Richard Law CFA's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -9.10% per trade.
1 Year
Richard Law CFAGoldman Sachs
Success Rate
0/1 ratings generated profit
0%
Average Return
-9.10%
Copying Richard Law CFA's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -9.10% per trade.
2 Years
Richard Law CFAGoldman Sachs
Success Rate
0/1 ratings generated profit
0%
Average Return
-9.10%
Copying Richard Law CFA's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -9.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

COAG Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
4
5
Buy
0
0
0
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
6
7
In the current month, COAG has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. COAG average Analyst price target in the past 3 months is 41.75.
Each month's total comprises the sum of three months' worth of ratings.

COAG Financial Forecast

COAG Earnings Forecast

Next quarter’s earnings estimate for COAG is -$23.25 with a range of -$23.98 to -$22.51. The previous quarter’s EPS was -$23.98. COAG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year COAG has its overall industry.
Next quarter’s earnings estimate for COAG is -$23.25 with a range of -$23.98 to -$22.51. The previous quarter’s EPS was -$23.98. COAG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year COAG has its overall industry.
No data currently available

COAG Sales Forecast

Next quarter’s sales forecast for COAG is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. COAG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year COAG has its overall industry.
Next quarter’s sales forecast for COAG is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. COAG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year COAG has its overall industry.

COAG Stock Forecast FAQ

What is COAG’s average 12-month price target, according to analysts?
Based on analyst ratings, Hemab Therapeutics Holdings, Inc.’s 12-month average price target is 41.75.
    What is COAG’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for COAG, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is COAG a Buy, Sell or Hold?
        Hemab Therapeutics Holdings, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Hemab Therapeutics Holdings, Inc.’s price target?
          The average price target for Hemab Therapeutics Holdings, Inc. is 41.75. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $50.00 ,the lowest forecast is $36.00. The average price target represents N/A Increase from the current price of N/A.
            What do analysts say about Hemab Therapeutics Holdings, Inc.?
            Hemab Therapeutics Holdings, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
              How can I buy shares of COAG?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.